# NCT00861705 (NCT00861705)

> Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00861705
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
- Interventions: Bevacizumab; Carboplatin; Cyclophosphamide; Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Paclitaxel
- Enrollment: 454
- Primary outcome: Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).
- Primary outcome: Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).

## Commentary we found

- X threads: 4
- Podcasts: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct00861705

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00861705", "email": "<work email>"}; the inbox owner confirms by the emailed link.